Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Sell
14
CTXR Quote, Financials, Valuation and Earnings
Last price:
$0.72
Seasonality move
:
-2.18%
Day range:
$0.71 - $0.82
52-week range:
$0.68 - $26.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.10x
Volume:
134.4K
Avg. volume:
504.1K
1-year change:
-95.83%
Market cap:
$6.3M
Revenue:
--
EPS (TTM):
-$5.77
Analysts' Opinion
-
Consensus RatingCitius Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.67, Citius Pharmaceuticals has an estimated upside of 678.92% from its current price of $0.73.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $0.73.
Fair Value
-
According to the consensus of 1 analyst, Citius Pharmaceuticals has 678.92% upside to fair value with a price target of $5.67 per share.
CTXR vs. S&P 500
-
Over the past 5 trading days, Citius Pharmaceuticals has underperformed the S&P 500 by -4.61% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Citius Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Citius Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Citius Pharmaceuticals reported revenues of --.
Earnings Growth
-
Citius Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Citius Pharmaceuticals reported earnings per share of -$1.30.
Enterprise value:
8.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.32x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$31.3M | -$38.8M | -$42.7M | -$9.3M | -$10M | |
| EBITDA | -$31.1M | -$38.6M | -$42.5M | -$9.3M | -$10M | |
| Diluted EPS | -$4.50 | -$6.52 | -$5.77 | -$1.45 | -$1.30 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.6M | $67.9M | $42.3M | $28.2M | $18.3M | |
| Total Assets | $35.3M | $137.5M | $111.7M | $97.4M | $120.7M | |
| Current Liabilities | $3.5M | $7.3M | $4.5M | $5.6M | $44.8M | |
| Total Liabilities | $9.5M | $13M | $10.7M | $12.1M | $51.8M | |
| Total Equity | $25.8M | $124.6M | $101M | $85.3M | $68.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28.5M | -$30.4M | -$26.8M | -$6.1M | -$4.7M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $13.8M | $12.5M | -- | $2.6M | |
| Free Cash Flow | -$28.5M | -$30.4M | -$26.8M | -$6.1M | -$4.7M | |
CTXR
Sector
Market Cap
$6.3M
$35.1M
Price % of 52-Week High
2.77%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-95.83%
-40.62%
Beta (5-Year)
0.903
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.78
200-day SMA
Sell
Level
$7.26
Bollinger Bands (100)
Sell
Level
1.13 - 3.13
Chaikin Money Flow
Sell
Level
-22.1M
20-day SMA
Sell
Level
$0.88
Relative Strength Index (RSI14)
Sell
Level
30.68
ADX Line
Sell
Level
11.07
Williams %R
Buy
Level
-85.2729
50-day SMA
Sell
Level
$1.25
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Sell
Level
-3.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
Stock Forecast FAQ
In the current month, CTXR has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CTXR average analyst price target in the past 3 months is $5.67.
-
Where Will Citius Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Citius Pharmaceuticals share price will rise to $5.67 per share over the next 12 months.
-
What Do Analysts Say About Citius Pharmaceuticals?
Analysts are divided on their view about Citius Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Citius Pharmaceuticals is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Citius Pharmaceuticals's Price Target?
The price target for Citius Pharmaceuticals over the next 1-year time period is forecast to be $5.67 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CTXR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Citius Pharmaceuticals is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CTXR?
You can purchase shares of Citius Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Citius Pharmaceuticals shares.
-
What Is The Citius Pharmaceuticals Share Price Today?
Citius Pharmaceuticals was last trading at $0.72 per share. This represents the most recent stock quote for Citius Pharmaceuticals. Yesterday, Citius Pharmaceuticals closed at $0.73 per share.
-
How To Buy Citius Pharmaceuticals Stock Online?
In order to purchase Citius Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is up 34.66% over the past day.
Buy
63
SKX alert for May 7
Skechers USA [SKX] is down 0.07% over the past day.
